Details for New Drug Application (NDA): 213154
✉ Email this page to a colleague
The generic ingredient in BOSENTAN is bosentan. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bosentan profile page.
Summary for 213154
| Tradename: | BOSENTAN |
| Applicant: | Natco Pharma Ltd |
| Ingredient: | bosentan |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213154
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BOSENTAN | bosentan | TABLET, FOR SUSPENSION;ORAL | 213154 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-340 | 68180-340-13 | 4 BLISTER PACK in 1 CARTON (68180-340-13) / 14 TABLET, FOR SUSPENSION in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 32MG | ||||
| Approval Date: | Feb 5, 2025 | TE: | AB | RLD: | No | ||||
| Regulatory Exclusivity Expiration: | Feb 14, 2026 | ||||||||
| Regulatory Exclusivity Use: | PATENT CHALLENGE | ||||||||
Complete Access Available with Subscription
